The British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and Scottish Intercollegiate Guidelines Network (SIGN) released joint guidance on ‘Asthma: diagnosis, monitoring and chronic asthma management’ on 27 November 2024. The guidance is the first collaboration of its kind between the organisations.
The guideline makes several recommendations, including advice to stop prescribing short-acting beta-2 agonist (SABA) inhalers without inhaled corticosteroids. While there has been a move towards this treatment regimen in recent years, this is the first recommendation of its kind in national guidance.
In this episode of The PJ Pod, Caitlin Killen, clinical editor, talks to Toby Capstick, consultant pharmacist in respiratory medicine at Leeds Teaching Hospitals NHS Trust, to learn more about the guidance and its implications for practice.
This episode was produced by Geoff Marsh.
Further resources
- SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries
- Asthma care initiative nominated for NHS Parliamentary Award
- Asthma + Lung UK Health advice resources
- Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site
- The PJ‘s respiratory tract disease hub page
Want to hear more from The PJ Pod? Follow us on Spotify, Google Podcasts, Apple Podcasts or other popular podcast platforms to listen to our latest episodes.
